Skip to content
AnalystLens

Rocket Lab 8-K Report, Regulation FD Disclosure (Aug 13, 2026)

Reports
Regulation FD·Other Events·Exhibits & Filings
Filing Date
Filed August 13, 2026
Period End
August 13, 2026
Security
RKLB
In the record · 2020–202610-K810-Q188-K88

RKLB filed 8 annual reports (10-K), 18 quarterly reports (10-Q) and 88 current reports (8-K) between 2020 and 2026.

  1. Material agreement8-K · Sep ’20Sep ’20
  2. Deal closed8-K · Jan ’22Jan ’22
  3. Leadership change8-K · Apr ’24Apr ’24
  4. Leadership change8-K · Nov ’25Nov ’25

01—Abstract

Summary

Summary of the 8-K filed August 13, 2026. Cited figures are marked; the original filing is the authoritative source.

Rocket Lab (RKLB) disclosed a replacement at-the-market (ATM) equity program with Deutsche Bank Securities and Wells Fargo Securities, under which it may sell common stock with an aggregate offering price of up to $1,944,369,826a.

The new agreement replaces the prior equity distribution agreement dated May 20, 2026, and carries forward the unsold amount under that program rather than adding capacity. The company also may enter into forward sale agreements, including initially priced and collared forward transactions. Sales commissions are capped at 2.00%b of gross proceeds, and the program may be terminated on two days' notice.

The company says the net proceeds will fund cash payments for its proposed acquisition of Iridium Communications and reduce its committed bridge facility. The offering is not conditioned on completing the Iridium deal, and the company says it will use any excess proceeds for growth, potential acquisitions, and general corporate purposes. A concurrent press release on the Iridium acquisition reports several milestones.

The Hart-Scott-Rodino waiting period expired at 11:59 p.m. ET on August 12, 2026, which clears U.S. antitrust review. Rocket Lab filed its Form S-4 registration statement, which is not yet effective, and FCC transfer-of-control applications were filed on August 10, 2026.

The company holds a $3.6 billionc 364-day senior secured bridge commitment and plans to replace it with permanent debt and equity. It also intends to seek lender consents to amend Iridium's $1.775 billion term loan so that facility can stay in place, which would reduce the bridge commitment. There is no assurance those consents will be obtained.

For investors, the key points are the scale of potential dilution, the reliance on equity and debt refinancing to fund a large acquisition, and the execution risk tied to lender consents, S-4 effectiveness, and shareholder approvals. Because the ATM sales can be suspended at any time and are subject to price and volume parameters, the timing and size of actual issuance are uncertain. Investors should monitor future prospectus supplements, the S-4 review process, and any Iridium lender consent results.

02—Key points

Key Highlights

  1. New ATM equity program with Deutsche Bank and Wells Fargo for up to $1.944 billion in common stock, replacing the May 20, 2026 agreement and carrying forward only the unsold amount (no incremental capacity).
  2. Net proceeds are earmarked to fund cash payments for the Iridium acquisition and reduce the $3.6 billion 364-day senior secured bridge facility, but the ATM is not conditioned on the deal closing.
  3. Forward sale structures are included, with initially priced forwards and collared forwards; the company receives no initial proceeds from borrowed-share sales and may owe cash or shares on cash or net share settlement.
  4. Sales agent commissions capped at 2.00% of gross proceeds; forward seller commissions also up to 2.00%, which reduces the company's net proceeds.
  5. HSR waiting period for the Iridium acquisition expired on August 12, 2026, clearing the U.S. antitrust waiting period.
  6. Form S-4 filed for the Iridium deal (not yet effective) and FCC transfer-of-control applications filed August 10, 2026, keeping the closing timeline dependent on further regulatory and shareholder steps.
  7. Plan to seek amendments to Iridium's $1.775 billion term loan to keep it in place and reduce the bridge commitment; lender consent is not assured.

03—Questions

Frequently Asked Questions

  1. How much stock can Rocket Lab sell under the new ATM program?

    Rocket Lab may sell shares with an aggregate offering price of up to $1,944,369,826. This amount is the unsold balance carried forward from the prior May 20, 2026 agreement, so the company is not adding new capacity.

  2. What will the proceeds be used for?

    The company currently intends to use all or part of the net proceeds to fund cash payments for the Iridium acquisition and to reduce commitments under its $3.6 billion bridge facility. If the Iridium deal does not close or excess proceeds remain, the funds would go toward growth, potential acquisitions, and general corporate purposes.

  3. Is the ATM dependent on the Iridium acquisition closing?

    No. The company states the offering is not conditioned on completing the Iridium acquisition, so shares may be sold regardless of whether that deal closes.

  4. What regulatory and approval milestones have been reached for the Iridium deal?

    The HSR waiting period expired on August 12, 2026, and FCC transfer-of-control applications were filed on August 10, 2026. The Form S-4 was filed but is not yet effective, so Rocket Lab cannot sell the securities described in it until it becomes effective.

  5. What are the main risks and costs for investors?

    Sales may be suspended at any time and depend on price and volume parameters, so there is no assurance any shares will be sold. Commissions of up to 2.00% reduce net proceeds, and forward settlements may require cash or share deliveries. Refinancing also depends on lender consents to amend Iridium's $1.775 billion term loan, which are not assured.

04—Continue

← View all 8-K filings